10x Genomics, Inc. (TXG) 追踪市盈率为负值 -65.8, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 追踪盈利收益率为 -1.52%.
本页证实的标准:
SharesGrow 综合评分： 40/100 其中 2/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2017 | -32.6 | 0.00 | -5.43 | 8.60 | - |
| 2018 | -6.3 | -0.02 | -3.21 | 4.83 | - |
| 2019 | -95.3 | 1.05 | 7.09 | 12.11 | - |
| 2020 | -26.4 | -0.05 | 19.38 | 47.93 | - |
| 2021 | -282.3 | 3.13 | 20.11 | 33.51 | - |
| 2022 | -25.0 | -0.14 | 5.15 | 8.03 | - |
| 2023 | -25.7 | -0.52 | 8.85 | 10.60 | - |
| 2024 | -9.5 | 0.31 | 2.44 | 2.83 | - |
| 2025 | -46.7 | 0.61 | 2.56 | 3.17 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2017 | $-1.62 | $71.09M | $-18.76M | -26.4% |
| 2018 | $-8.40 | $146.31M | $-112.49M | -76.9% |
| 2019 | $-0.80 | $245.89M | $-31.25M | -12.7% |
| 2020 | $-5.37 | $298.85M | $-542.73M | -181.6% |
| 2021 | $-0.53 | $490.49M | $-58.22M | -11.9% |
| 2022 | $-1.46 | $516.41M | $-166M | -32.1% |
| 2023 | $-2.18 | $618.73M | $-255.1M | -41.2% |
| 2024 | $-1.52 | $610.79M | $-182.63M | -29.9% |
| 2025 | $-0.35 | $642.82M | $-43.54M | -6.8% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-0.83 | $-1.38 – $-0.09 | $612.59M | $607.85M – $618.09M | 8 |
| 2027 | $-0.64 | $-1.26 – $0.49 | $656.67M | $635.09M – $670.49M | 8 |
| 2028 | $-0.51 | $-0.86 – $-0.07 | $708.97M | $706.91M – $711.02M | 10 |
| 2029 | $-0.37 | $-0.38 – $-0.36 | $777.69M | $760.74M – $795.23M | 4 |
| 2030 | $-0.36 | $-0.37 – $-0.35 | $841.03M | $822.71M – $860.01M | 4 |
